Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Batra 2022 Abstract Bioblast"

From Bioblast
m (Plangger Mario moved page Batra 2022 Absract Bioblast to Batra 2022 Abstract Bioblast without leaving a redirect)
Line 1: Line 1:
{{Abstract
{{Abstract
|title=Subramaniam S, Jeet V, Gunter JH, Clements JA, Popat A, Batra JΒ  (2022) Nano-encapsulated Dichloroacetophenone (DAP) essential mitochondrial enzyme, is a potential inhibitor of prostate cancer cell growth
|title=Subramaniam S, Jeet V, Gunter JH, Clements JA, Popat A, Batra JΒ  (2022) Nano-encapsulated Dichloroacetophenone (DAP) essential mitochondrial enzyme, is a potential inhibitor of prostate cancer cell growth
|info=
|authors=Subramaniam Sugarniya, Jeet Varinder, Gunter Jennifer H,Clements Judith A, Popat Amirali, Batra Jyotsna
|authors=Subramaniam Sugarniya, Jeet Varinder, Gunter Jennifer H,Clements Judith A, Popat Amirali, Batra Jyotsna
|year=2022
|year=2022
|event=[[Bioblast 2022]]
|event=[[Bioblast 2022]]
|abstract=
|abstract=Our previous genetic studies identified Pyruvate Dehydrogenase Kinase 1 (PDK1) as akey gene regulated by microRNA in an allele dependent manner. Metabolic reprogramming is beneficial for tumour cell. We showed that PDK1 is an oncogene and plays a major role in glycolytic pathway in prostate cancer. Recently, targeting metabolic pathways with drugs has emerged as potential therapy in prostate cancer. In this study we found that DAP is more potent than DCA in inhibiting prostate cancer cell proliferation, migration, colony formation and induced apoptosis. Further, DAP reduced extra cellular acidification rate in prostate cancer cells. In addition, lactoferrin conjugated DAP particle inhibited proliferation of prostate cancer cells at a low dose compared to DAP alone.Β  DAP and lactoferrin conjugated DAP nanoparticles selectively caused a reduction in prostate cancer cell proliferation compared to normal derived cell line. Furthermore, lactoferrin conjugated DAP particles suppressed both glycolytic and oxidative phosphorylation pathway in prostate cancer cells. DAP and lactoferrin conjugated DAP particles suppressed the cell viability of docetaxel resistant cell line, PC3 RX-DT2R in a dose dependent manner. Overall, our results demonstrate that targeting glycolytic pathway via PDK1 by DAP could be therapeutic strategy in prostate cancer. Nanoparticle based DAP delivery may improve the efficiency in targeting prostate tumour metabolism.
Our previous genetic studies identified Pyruvate Dehydrogenase Kinase 1 (PDK1) as akey gene regulated by microRNA in an allele dependent manner. Metabolic reprogramming is beneficial for tumour cell. We showed that PDK1 is an oncogene and plays a major role in glycolytic pathway in prostate cancer. Recently, targeting metabolic pathways with drugs has emerged as potential therapy in prostate cancer. In this study we found that DAP is more potent than DCA in inhibiting prostate cancer cell proliferation, migration, colony formation and induced apoptosis. Further, DAP reduced extra cellular acidification rate in prostate cancer cells. In addition, lactoferrin conjugated DAP particle inhibited proliferation of prostate cancer cells at a low dose compared to DAP alone.Β  DAP and lactoferrin conjugated DAP nanoparticles selectively caused a reduction in prostate cancer cell proliferation compared to normal derived cell line. Furthermore, lactoferrin conjugated DAP particles suppressed both glycolytic and oxidative phosphorylation pathway in prostate cancer cells. DAP and lactoferrin conjugated DAP particles suppressed the cell viability of docetaxel resistant cell line, PC3 RX-DT2R in a dose dependent manner. Overall, our results demonstrate that targeting glycolytic pathway via PDK1 by DAP could be therapeutic strategy in prostate cancer. Nanoparticle based DAP delivery may improve the efficiency in targeting prostate tumour metabolism.
Β 
Β 
Β 
|keywords=metabolism, pyruvate dehydrogenase kinase 1, dichloroacetophenone, prostate cancer, lactoferrin nanoparticle
|keywords=metabolism, pyruvate dehydrogenase kinase 1, dichloroacetophenone, prostate cancer, lactoferrin nanoparticle
|mipnetlab=
|journal=
|articletype=Abstract
|articletype=Abstract
}}
}}
Β 
{{Labeling
|articletype=Abstract
}}
__NOTOC__
__NOTOC__
== Affiliations and author contributions ==
== Affiliations and author contributions ==
Sugarniya Subramaniam<sup>1,2,5</sup>, Varinder Jeet <sup>1,2,5</sup>, Jennifer H. Gunter<sup>1,2,5</sup>, Judith A. Clements<sup>1,2,5</sup>,Β  Amirali Popat<sup>3,4,5</sup> and Jyotsna Batra <sup>1,2,3*</sup>
::::Sugarniya Subramaniam<sup>1,2,5</sup>, Varinder Jeet <sup>1,2,5</sup>, Jennifer H. Gunter<sup>1,2,5</sup>, Judith A. Clements<sup>1,2,5</sup>,Β  Amirali Popat<sup>3,4,5</sup> and Jyotsna Batra <sup>1,2,3*</sup>


1 School of Biomedical Sciences; Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia<br>
::::#School of Biomedical Sciences; Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia<br>
Β 
::::#Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba, Australia<br>
2 Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba, Australia<br>
::::#School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia<br>
Β 
::::#Mater Research Institute, Woolloongabba, QLD, Australia<br>
3 School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia<br>
::::#Translational Research Institute, Woolloongabba, QLD, Australia<br>
Β 
4 Mater Research Institute, Woolloongabba, QLD, Australia<br>
Β 
5 Translational Research Institute, Woolloongabba, QLD, Australia<br>


*Jyotsna.batra@qut.edu.au
*Jyotsna.batra@qut.edu.au
Line 37: Line 25:
== Help ==
== Help ==
* [[MitoPedia: Terms and abbreviations]]
* [[MitoPedia: Terms and abbreviations]]
{{Labeling
|area=
|diseases=
|tissues=
|preparations=
|topics=
|couplingstates=
|instruments=
|journal=
|articletype=Abstract
}}

Revision as of 12:24, 19 April 2022

Subramaniam S, Jeet V, Gunter JH, Clements JA, Popat A, Batra J (2022) Nano-encapsulated Dichloroacetophenone (DAP) essential mitochondrial enzyme, is a potential inhibitor of prostate cancer cell growth

Link:

Subramaniam Sugarniya, Jeet Varinder, Gunter Jennifer H, Clements Judith A, Popat Amirali, Batra Jyotsna (2022)

Event: Bioblast 2022

Our previous genetic studies identified Pyruvate Dehydrogenase Kinase 1 (PDK1) as akey gene regulated by microRNA in an allele dependent manner. Metabolic reprogramming is beneficial for tumour cell. We showed that PDK1 is an oncogene and plays a major role in glycolytic pathway in prostate cancer. Recently, targeting metabolic pathways with drugs has emerged as potential therapy in prostate cancer. In this study we found that DAP is more potent than DCA in inhibiting prostate cancer cell proliferation, migration, colony formation and induced apoptosis. Further, DAP reduced extra cellular acidification rate in prostate cancer cells. In addition, lactoferrin conjugated DAP particle inhibited proliferation of prostate cancer cells at a low dose compared to DAP alone. DAP and lactoferrin conjugated DAP nanoparticles selectively caused a reduction in prostate cancer cell proliferation compared to normal derived cell line. Furthermore, lactoferrin conjugated DAP particles suppressed both glycolytic and oxidative phosphorylation pathway in prostate cancer cells. DAP and lactoferrin conjugated DAP particles suppressed the cell viability of docetaxel resistant cell line, PC3 RX-DT2R in a dose dependent manner. Overall, our results demonstrate that targeting glycolytic pathway via PDK1 by DAP could be therapeutic strategy in prostate cancer. Nanoparticle based DAP delivery may improve the efficiency in targeting prostate tumour metabolism.

β€’ Keywords: metabolism, pyruvate dehydrogenase kinase 1, dichloroacetophenone, prostate cancer, lactoferrin nanoparticle


Labels:








Affiliations and author contributions

Sugarniya Subramaniam1,2,5, Varinder Jeet 1,2,5, Jennifer H. Gunter1,2,5, Judith A. Clements1,2,5, Amirali Popat3,4,5 and Jyotsna Batra 1,2,3*
  1. School of Biomedical Sciences; Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
  2. Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba, Australia
  3. School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
  4. Mater Research Institute, Woolloongabba, QLD, Australia
  5. Translational Research Institute, Woolloongabba, QLD, Australia
  • Jyotsna.batra@qut.edu.au

Help